Instem plc JOINN Laboratories China Purchases Provantis
January 10 2013 - 2:01AM
RNS Non-Regulatory
TIDMINS
Instem plc
10 January 2013
10 January 2013
Instem plc
("Instem", the "Company" or the "Group")
JOINN Laboratories China Purchases Provantis
Instem plc (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces today that
JOINN Laboratories (JOINN) has purchased its Provantis(R)
preclinical software solution suite to automate processes within
its China-based facilities located in Beijing and Suzhou.
JOINN provides drug screening, efficacy studies,
pharmacokinetics studies, safety evaluations, clinical trials and
final drug registration services. Founded in 1995, JOINN was
China's first preclinical laboratory to be inspected by the U.S.
Food and Drug Administration (FDA) for Good Laboratory Practice
(GLP) compliance, and now supports clients from more than 20
provinces across China, Japan and Europe. Within the United States,
JOINN provides international clients with technical consulting
services for FDA drug registration.
Following a comprehensive evaluation of software technologies,
Instem was selected due to its presence and experience within China
and its leading position in the global early development safety
assessment market. Utilising Provantis, JOINN will further improve
the quality of its study processes and deliver demonstrable
efficiency improvements in support of its mission to provide
services for drug innovation to benefit worldwide public
health.
Provantis is a modern, fully integrated software system for
single users and global organisations engaged in preclinical
evaluation studies. Orchestrating every facet of preclinical drug
safety assessment, Provantis streamlines processes and workflows
with straightforward, intuitive functionality for simple or complex
studies within a GLP or non-GLP environment, on-site or over the
Web.
Phil Reason, CEO of Instem plc, commented: "We are delighted to
welcome JOINN, China's largest provider of preclinical studies, to
the Instem client community. Their order for 200 licensed users
adds significantly to the leadership position we already enjoy in
the China market and is a further indication of the longer term
growth potential in what is already the third largest
pharmaceutical market in the world."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 7496 3000
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT solutions to the early
development healthcare market. Instem's pre-clinical study
management solutions accelerate drug and chemical development by
increasing productivity, automating processes and enhancing
practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China,
India and Japan, including 16 of the top 20 pharmaceutical and
biotech companies such as GlaxoSmithKline and AstraZeneca. The
Group employs over 110 people in seven offices in the US, UK, China
and India; and has a full service distributor in Japan. It is
estimated that approximately half of the world's pre-clinical drug
safety data has been collected over the last 20 years via Instem
software, making Instem an ideal partner to help unlock the
scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website,
www.instem.com, or its investor centre
http://investors.instem.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFSDLIIAIIV
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024